Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Iowa for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Iowa only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Iowa (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

James Singer (NPI 1427369107)

Field	Value
Entity Type	Individual
Organization	James Singer
Address	1501 50th St., Ste 133
City	West Des Moines
State	IA
ZIP	50266
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	June 28, 2010

Payer Source	Total Paid
Medicare	$4.1M
Medicaid	$0

Key Findings

This provider is effectively single‑payer at scale: Total Medicare revenue is $4.1M and there is no Medicaid billing on file, so Medicare drives the entirety of recorded public-payer activity. Analysts should treat Medicare patterns as representative of the practice’s public-revenue footprint rather than balancing Medicare vs. Medicaid dynamics.

Revenue is highly concentrated in a small number of intravitreal therapy codes: the top three Medicare codes account for 89.3% of the provider’s Medicare revenue, led by J2777 (69.4%), followed by J0178 (14.5%) and 67028 (5.4%). This concentration signals a business model centered overwhelmingly on anti‑VEGF/faricimab biologic injections and standalone intravitreal procedures rather than broad general ophthalmology services.

Clinical/service-line implication — retina/injection‑focused practice: the dominance of J2777, J0178 and 67028 aligns with a retina specialist workflow that performs high volumes of intravitreal injections for retinal vascular disease and age‑related macular degeneration, supported by diagnostic imaging and procedural follow‑up rather than primarily office-based E/M visits. The presence of high-volume imaging codes such as 92134 further supports a procedure-first retina clinic model.

Statistical outliers and competitive standing — J2777 and retinal imaging: J2777 (faricimab) is an extreme outlier nationally, generating $2.8M (69.4% of this provider's Medicare revenue) and ranking #21 of 2039 providers (99th percentile); similarly, 92134 (retinal imaging) is an extreme outlier with 3.3K claims and $91.5K, ranking #301 of 26868 providers (99th percentile). These positions indicate the provider is a dominant national outlier for faricimab administration and for retinal imaging volume, which may reflect clinic specialization, high patient throughput, or site‑level infusion/injection capacity.

Middle‑tier and routine code volumes: some high-cost biologic and E/M codes show more typical volumes — J0178 (aflibercept) produced $590.6K (14.5% of Medicare revenue) and ranks #1430 of 3204 providers (55th percentile), and J2778 (ranibizumab) is at a 40th percentile ranking. These placements suggest that while the provider is extraordinarily heavy in faricimab use, their utilization of other common anti‑VEGF agents is within the expected national range and not unusually elevated.

Use of unclassified biologics and ancillary procedures: J3590 (unclassified biologics) appears notably above typical national volume, with 848 claims and $59.4K (rank #25 of 631 providers, 96th percentile), indicating supplemental biologic or injectable product billing beyond the main named agents. Ancillary retinal procedures such as 67028 (isolated intravitreal injection) and 92134 (diagnostic retinal imaging) round out the mix and are consistent with an injection‑centric retina practice rather than primarily surgical retina work.

Operational and contracting implications: the very high revenue share from J2777 (69.4%) creates concentration risk — any payer formulary changes, reimbursement shifts, or clinical guideline updates impacting faricimab could materially affect this provider’s Medicare revenue. Given the provider’s extreme national ranking on J2777 and high imaging throughput, payers and contracting teams should prioritize review of utilization patterns, supply costs, and site-of-care arrangements for intravitreal biologics when assessing network value and reimbursement terms.

Provider tenure and market presence: the NPI was enumerated 2010-06-28 (~16 years ago), indicating a long-established practice presence; combined with the high national rank on select retinal codes, this suggests an experienced retina specialist with sustained, procedure-focused throughput rather than a recent entrant or low-volume practitioner.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

19 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	97,620	$30	$2.8M
J0178	Injection, aflibercept, 1 mg	870	$680	$590.6K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	2,450	$90	$220.7K
J2778	Injection, ranibizumab, 0.1 mg	520	$180	$93.7K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	3,270	$30	$91.5K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	1,140	$60	$69.2K
J3590	Unclassified biologics	850	$70	$59.4K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	200	$150	$31.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	310	$90	$28K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	160	$120	$18.4K

Showing 1–10 of 19

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 19 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Iowa Distribution

James Singer — 3 of 19 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Iowa

Full comparison — all codes billed, vs. state median

19 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2777	6	20	43,140	$30	$1.7M
J0178	18	40	640	$690	$760.2K
J2778	14	20	780	$180	$259.9K
67028	8	60	420	$80	$80.6K
J7312	5	10	200	$160	$32.9K
J3590	3	30	140	$100	$26.7K
92014	488	500	200	$70	$19.8K
99214	959	4,690	100	$70	$14.4K
67041	1	10	10	$980	$11.7K
99213	944	4,740	100	$50	$8K

Showing 1–10 of 19

Related Providers

Other providers that share a Tax Identification Number (TIN) with James Singer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Thomas Buroker	IA	Medical Oncology Physician	$9.4M	$0
Kyle Alliman	IA	Ophthalmology Physician	$8.7M	$0
Alex Kartvelishvili	IA	Ophthalmology Physician	$8.1M	$0
Paul Boeke	IA	Ophthalmology Physician	$7.1M	$0
Austin Strohbehn	IA	Retina Specialist (Ophthalmology) Physician	$5.8M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Robert Behrens	IA	Medical Oncology Physician	$5.2M	$0
Matthew Mcknight	IA	Foot & Ankle Surgery Podiatrist	$4.7M	$23.5K
Christopher Haupert	IA	Retina Specialist (Ophthalmology) Physician	$3.9M	$0
David Massop	IA	Retina Specialist (Ophthalmology) Physician	$3.9M	$0

Nearby Providers

Other providers in the same ZIP code as James Singer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Iowa Physicians Clinic Medical Foundation	IA	General Practice Physician	$0	$102.7M
Link Associates	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$83.3M
Iowa Family Services, Inc	IA	Community/Behavioral Health Agency	$0	$9.9M
Revell-warrington Dental PC	IA	Pediatric Dentistry	$0	$9.2M
Csa	IA	Community/Behavioral Health Agency	$0	$8.8M
City Of West Des Moines	IA	Land Ambulance	$726.2K	$5.1M
Wolfe Surgery Center, LLC	IA	Ambulatory Surgical Clinic/Center	$4.1M	$1.3M
Iowa Home Care, LLC	IA	Home Health Agency	$0	$5.4M
The Iowa Clinic PC	IA	Family Medicine Physician	$0	$5.4M
Divine Touch Of Iowa LLC	IA	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$4.8M

James Singer — Billing Profile & Reimbursement Data

Sign up for James Singer — Billing Profile & Reimbursement Data policy alerts

James Singer — Billing Profile & Reimbursement Data

Sign up for James Singer — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References